Truist raised the firm’s price target on American Healthcare REIT (AHR) to $29 from $27 and keeps a Buy rating on the shares. The REIT saw much stronger Q3 results and FY24 guidance than anticipated, and while the stock is up 123% since its IPO vs. 13% for the VNQ, there is additional upside potential, the analyst tells investors in a research note. Truist adds it is projecting the strongest three- and five-year earnings growth rate for American Healthcare in its healthcare REIT coverage universe.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHR:
- American Healthcare REIT, Inc. Reports Q3 2024 Results
- American Healthcare REIT Reports Q3 2024 Financial Results
- American Healthcare REIT raises FY24 NFFO to $1.40-$1.43 from $1.23-$1.27
- American Healthcare REIT reports Q3 NFFO 36c, consensus 32c
- American Healthcare REIT management to meet with JMP Securities